Biomarin Pharmaceutical Inc (BMRN)

BMRN (NASDAQ:Drugs) EQUITY
$92.57
pos +0.47
+0.51%
Today's Range: 91.40 - 93.21 | BMRN Avg Daily Volume: 1,330,200
Last Update: 09/20/17 - 4:00 PM EDT
Volume: 1,153,233
YTD Performance: 11.18%
Open: $92.13
Previous Close: $92.10
52 Week Range: $62.12 - $148.92
Oustanding Shares: 175,268,321
Market Cap: 16,121,180,166
6-Month Chart
TheStreet Ratings Grade for BMRN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 14 12 11 11
Moderate Buy 2 2 2 2
Hold 4 3 2 2
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.48 1.44 1.37 1.37
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -91.07
Price Earnings Comparisons:
BMRN Sector Avg. S&P 500
-91.07 0.00 36.80
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
0.82% -6.13% 31.85%
GROWTH 12 Mo 3 Yr CAGR
Revenue 25.50 1.00 0.26
Net Income 0.00 2.60 0.00
EPS 0.00 2.00 0.00
Earnings for BMRN:
EBITDA -0.16B
Revenue 1.12B
Average Earnings Estimates
Qtr (09/17) Qtr (12/17) FY (12/17) FY (12/18)
Average Estimate $-0.09 $-0.33 $-0.71 $-0.35
Number of Analysts 12 11 12 11
High Estimate $-0.02 $-0.28 $-0.59 $0.48
Low Estimate $-0.20 $-0.40 $-0.85 $-0.88
Prior Year $-0.26 $-0.53 $-3.81 $-0.71
Growth Rate (Year over Year) 66.35% 38.59% 81.26% 50.48%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
There still will be winners and losers, but the new administration's FDA is a net plus for the industry.
The FAANG stocks will underperform, banks will do well and biotech merger action will pick up.
The FAANG stocks will underperform, banks will do well and biotech merger action will pick up.
It's a wonder to me how split this market really is.
Home builders make up the second-largest allocation in my portfolio, behind biotech.
Drug giants with money to spend and a friendlier regulatory environment should spur deals.
The pharmaceutical stock is about to go from sideways to up.
Bearish
Nov 07, 2016 | 7:21 AM EST
BMRN was downgraded from Overweight to Neutral, Piper Jaffray said. $84 price target. Valuation call, given limited visibility.
Overall, this is still a good environment for stock picking.
They're striking while the iron is hottest to raise money, reduce debt.

Columnist Conversations

Now that AAPL has violated the shorter term support, these are the two areas I have to consider for new buy en...
The symmetry is holding up in MCD.  Target 1 is 163.34 if we continue to hold above here!  ...
As far as TSLA is concerned, I still have a higher target above the market at the 409 area.  I stated in ...
The TLT setup discussed in my last commentary is a bust. Key support was violated and it violated the recent l...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.